GlobeNewswire

CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models

Del

Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft (PDX) models of prostate cancer.

Prostate cancer is the second most common cancer in males, impacting more than 1 million new patients worldwide each year. The disease has long been underrepresented at the preclinical modeling stage of drug development, due to the difficulty in establishing PDX models. CrownBio is committed to providing clinically relevant solutions for diseases with high unmet need.

PDX are the most translatable preclinical models currently available, directly derived from patient tissue and reflecting the variability and heterogeneity seen in patient populations. They also represent the tumor microenvironment (TME) more accurately than in vitro options, particularly when transplanted orthotopically, therefore they are the model of choice for preclinical drug discovery and development. CrownBio’s goal is to recapitulate the diversity and complexity of human cancer biology in the laboratory.

“The biopharmaceutical research community has been lacking in well-characterized prostate cancer PDX models. They are extremely difficult to generate and grow in mice due to multiple issues,” said Dr. Henry Li, SVP of Global Scientific Research and Innovation. He continued; “I am very excited to announce the successful validation of models derived from both castration resistant and hormone sensitive primary tissue to add to our extensive collection of more than 2,500 PDX models.”

“At CrownBio we have dedicated significant efforts to the development of these models. We will continue to invest in a diverse collection of models that represents patient populations from different backgrounds globally. Due to their unique nature, we anticipate high demand for these clinically relevant models,” commented Dr. Jean-Pierre Wery, CEO of Crown Bioscience.

To learn more about the CrownBio portfolio of in vivo and in vitro prostate cancer models, visit: https://www.crownbio.com/prostate-cancer-preclinical-models

About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Family of Constant-Current Dimmable Buck LED Drivers18.12.2018 11:00Pressemelding

1.5A, 3A Buck LED Drivers Target ISO26262 automotive and industrial applications MILPITAS, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AMS, the Analog Mixed-Signal division of ISSI, has introduced a family of switching buck LED Drivers for automotive and industrial applications. This family of highly integrated switching constant current buck LED Drivers are targeted for 12V/24V battery connected, space-constrained, electromagnetic (EMC) sensitive applications such as Headlight, Front and Rear Fog lights, Day time Running lights to name a few. The device family supports a wide DC voltage input range of 4.5V to 38V and outputs a 5% regulated current of 1.5A or 3A; depending on the particular device, see table. The integrated power MOSFET is configured to switch in the constant on-time mode delivering true average current. Switching at a frequency of up to 2MHz which is adjustable with an external resistor, these buck LED Drivers can use smaller output inductor and capacitor values thereby

John Charman Appointed Chief Executive Officer of Sompo Holdings Overseas Insurance Business and Nigel Frudd Appointed as Chief Executive Officer of Sompo International18.12.2018 10:13Pressemelding

Mr. Charman and Mr. Frudd to Join Sompo Holdings New Global Executive Committee PEMBROKE, Bermuda, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Sompo International Holdings Ltd. (Sompo International), a Bermuda-based specialty provider of property and casualty insurance and reinsurance, announced today that effective April 1, 2019, Mr. John Charman, currently Chairman of the Board of Directors and Chief Executive Officer of Sompo International, will be promoted to Chief Executive Officer of Overseas Insurance Business in Sompo Holdings, Inc. (Sompo Holdings). This segment of Sompo Holdings’ business currently represents more than 27% of Sompo Holdings Group’s adjusted profit, employing around 9,000 people in 30 countries and regions and is projected to have more than $10 billion in gross premiums by 2020. In such capacity, Mr. Charman will join the new Global Executive Committee of Sompo Holdings (Global ExCo) which will be established in April 2019 to provide expertise and input on group-wide st

LeddarTech Selects BlackBerry’s QNX Operating System for its Auto and Mobility LiDAR Platform18.12.2018 06:05Pressemelding

The QNX OS for Safety runs the software at the core of LeddarTech’s innovative automotive LiDAR development platform that enables the design of differentiated LiDAR solutions tailored to specific autonomous driving applications. QUEBEC CITY, Dec. 18, 2018 (GLOBE NEWSWIRE) -- LeddarTech , an industry leader providing the most versatile, scalable Auto and Mobility LiDAR Platform, today announced it has selected the QNX OS for Safety as the operating system for its LeddarSP Digital Signal Processing library. The LeddarSP software works in tandem with LeddarCore systems-on-chip to form the LeddarEngine, which is embedded at the heart of a variety of LiDAR sensor designs that enable ADAS and autonomous driving applications. “We believe that there is no safety without security,” said Grant Courville, VP of QNX Product Management and Strategy at BlackBerry. “We are thrilled to provide LeddarTech, an industry leader in LiDAR technology, with the reliable foundation necessary for building compe

Align Technology Reaches 6 Millionth Invisalign® Patient Milestone With Tween Patient From China18.12.2018 02:30Pressemelding

12-year old Yuzhe Wang from Beijing, China is in treatment with Invisalign trained doctor Jiawei Wo using Invisalign Comprehensive with Mandibular Advancement Accelerating adoption of Invisalign clear aligner treatment globally reflects Align’s continued investment in product innovation and commitment to international expansion BEIJING and SAN JOSE, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN) today announced that over 6 million patients have begun treatment with Invisalign - the most advanced clear aligner system in the world, including 1.4 million teenage patients*. This is a significant milestone for the company and the over 150,000 Invisalign-trained doctors worldwide, reflecting accelerating adoption of Invisalign treatment by adults and teens alike. The 6 millionth Invisalign patient, Yuzhe Wang, is a 12-year-old student of the International School of Beijing, who began treatment in October 2018 using Invisalign Comprehensive with Mandibular Adv

Euronet USA’s Advanced Technology Solution Selected by Banco de Moçambique for Their National Payment Network18.12.2018 00:15Pressemelding

LEAWOOD, Kan., Dec. 17, 2018 (GLOBE NEWSWIRE) -- On Monday, December 10, 2018, Euronet USA, Inc. signed an agreement with Banco de Moçambique to provide a modernized national payment network solution to Mozambique. Under the agreement, Euronet will provide state-of-the-art software for the financial system in Mozambique. Euronet’s superior technology combined with over 40 years of experience in the payments landscape makes them well suited to deliver a robust solution to meet the country’s existing and future requirements. This arrangement recognizes Euronet’s leadership position in the region as this solution will be used to drive all payment processing in the country. “We are extremely honored to grow our strong relationship with the country of Mozambique, by providing advanced and scalable products and services that we deploy successfully around the world,” said Cindy Ashcraft, Vice President of Euronet Worldwide and Managing Director of Euronet Software Solutions, headquartered in

ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 1017.12.2018 17:52Pressemelding

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Nature Medicine. “It was enormously gratifying to see robust improvements in visual acuity and significant augmentations in the patient’s ability to detect lights, and impressive to observe these effects within the first three months following a single injection,” said Professor Artur V. Cideciyan, Ph.D., who was one of the co-investigators at the Scheie Eye Institute of the University of Pennsylvania. “LCA10 is a severe form of childhood blindness and this is a major step forward in the treatment of these previously